TCL Archive FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC. March 30, 2001
TCL Archive FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says. April 1, 2005
TCL Archive Tracor Lands Second Biggest NCI Contract-$6.6 Million To Manage Commercial Labs’ Portion Of Bioassay Program April 19, 1974
